Care Access Research, AstraZeneca Partner on COVID-19 Antibody Trial

Care Access Research, a decentralized research organization (DRO) that connects physicians and research experts, entered a collaboration with AstraZeneca to accelerate a clinical trial in the U.S. for AZD7442, AstraZeneca’s long-acting monoclonal antibody (LAAB) combination for the potential prevention of COVID-19.

Care Access is supporting the Phase III trial called STORM CHASER, which will assess the safety and efficacy of AZD7442 for post-exposure prophylaxis and pre-emptive treatment in approximately 1,125 participants in the U.S. and UK. Participants will include adults over 18 following exposure to SARS-COV-2 and who are therefore at appreciable risk of developing COVID-19.

The companies are collaborating to rapidly develop, deploy, and manage clinical research sites across the country using Care Access’ Mobile Sites On Demand capability to bring research capabilities – including people, equipment, software, and processes – to places that would otherwise have limited access to clinical trials. Care Access is equipped with the operational systems and staff required to mobilize the entire clinical research operation and bring it directly to patients.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense; under Contract No. W911QY-21-9-0001.